What is ALS?
Amyotrophic Lateral Sclerosis, often called ALS or Lou Gehrigs disease, is a progressive neurodegenerative disorder that attacks the motor neurons responsible for controlling voluntary muscles. As these nerves deteriorate, the brains ability to send signals to the muscles diminishes, leading to weakness, atrophy, and eventually paralysis. The disease typically spares the sensesvision, hearing, touch, smell, and taste remain intact.
Most people receive an ALS diagnosis between the ages of 55 and 75, and the condition occurs slightly more often in men than women. While the majority of cases are classified as sporadic (no clear family history), about 510% are familial, linked to inherited gene mutations.
Common Symptoms
Early signs of ALS are often subtle and can vary widely. Typical symptoms include:
- Muscle weakness in the hands, arms, legs, or diaphragm
- Twitching (fasciculations) or cramping of muscles
- Difficulty speaking (dysarthria) or swallowing (dysphagia)
- Stiffness or spasticity
- Fatigue and loss of coordination
As the disease progresses, patients may experience:
- Severe respiratory weakness requiring ventilatory support
- Complete loss of voluntary movement while retaining eye movement and consciousness
- Weight loss due to difficulty eating
Because cognition is generally preserved, many individuals remain fully aware of their physical decline, which can profoundly affect mental health.
Causes and Risk Factors
The exact cause of ALS remains unknown, but research points to a combination of genetic, molecular, and environmental factors.
Genetic Factors
More than 30 genes have been implicated in familial ALS. The most common mutations occur in SOD1, C9orf72, FUS, and TARDBP. These genes affect protein folding, RNA processing, and cellular stress responses.
Environmental and Lifestyle Factors
- Exposure to certain toxins (e.g., pesticides, heavy metals)
- Military servicehigher incidence among veterans
- Smoking and high bodymass index may modestly increase risk
Age, gender, and a family history of neurodegenerative disease also influence susceptibility.
How ALS Is Diagnosed
There is no single test for ALS. Diagnosis relies on a careful clinical evaluation combined with exclusion of other conditions.
Typical Diagnostic Process
- Neurological examination: Assessment of muscle strength, reflexes, and coordination.
- Electromyography (EMG) and nerveconduction studies: Detect denervation and rule out peripheral neuropathies.
- MRI of the brain and spinal cord: Excludes structural lesions.
- Blood and urine tests: Screen for metabolic, inflammatory, or infectious causes.
- Genetic testing: Recommended when a family history suggests hereditary ALS.
Because early symptoms can mimic other disorders, it may take several months to confirm ALS.
Treatment, Care, and Quality of Life
Currently, no cure exists, but several interventions can slow progression, manage symptoms, and improve quality of life.
Pharmacologic Options
- Riluzole: The first FDAapproved drug; modestly extends survival by reducing glutamate toxicity.
- Edaravone: An antioxidant shown to slow functional decline in a subset of patients.
- Experimental agents (e.g., antisense oligonucleotides for SOD1 or C9orf72) are in clinical trials.
Multidisciplinary Care
Involvement of neurologists, respiratory therapists, speechlanguage pathologists, dietitians, and occupational therapists has been shown to lengthen survival and improve daily functioning.
Assistive Technologies
- Communication devices (eyetracking or braincomputer interfaces)
- Powered wheelchairs and adaptive equipment
- Noninvasive ventilation (BiPAP) and, when needed, invasive ventilation
Psychosocial Support
Psychological counseling, support groups, and palliativecare services are essential for patients and families coping with the emotional burden of ALS.
Current Research & Emerging Therapies
Research is rapidly advancing in three main areas:
- Genetic therapies: Antisense oligonucleotides (ASOs) that target mutant transcripts have demonstrated efficacy in earlyphase trials for SOD1related ALS.
- Stemcell approaches: Clinical studies are exploring intrathecal infusion of mesenchymal stem cells to deliver neurotrophic factors.
- Neuroinflammation modulation: Drugs that dampen microglial activation (e.g., masitinib) aim to reduce diseasedriven inflammation.
Large collaborative networks such as the ALS Associations ALS Therapy Development Institute and the international COST Action are accelerating data sharing and trial recruitment.
For detailed trial information, see ClinicalTrials.gov (search ALS).
Useful Resources
- The ALS Association patient guides, research updates, and community forums.
- Muscular Dystrophy Association ALS information on care coordination.
- ClinicalTrials.gov searchable database of ongoing ALS studies.
- National Institute of Neurological Disorders and Stroke scientific overview and funding opportunities.
